Rapt Therapeutics Inc.
RAPT Therapeutics Files Investor Presentation Slides
Summary
RAPT Therapeutics, Inc. is filing investor presentation slides as Exhibit 99.1, which the Company may use from time to time in conversations with investors and analysts. The presentation discusses the development of RPT904, a novel anti-IgE antibody designed for less frequent dosing and greater compliance, with potential applications in Food Allergy (FA) and Chronic Spontaneous Urticaria (CSU). Clinical milestones are anticipated over the next two years, including Phase 2b trial data in FA expected in 1H 2027.
Profitelligence Alerts
Get alerts for RAPT
Be first to know when Rapt Therapeutics Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Rapt Therapeutics Inc.
Rapt Therapeutics Inc. is a biotechnology firm focused on the discovery, development, and commercialization of oral small molecule therapies for oncology and inflammatory diseases. Its primary mission is to create novel treatments by harnessing its proprietary drug discovery platform, which targets key pathways responsible for the progression of these complex conditions. Rapt Therapeutics is notably advancing its development of selective inhibitors for immune checkpoint inhibitors within the broader cancer treatment landscape, potentially enhancing the efficacy of existing therapies. The company's pipeline includes multiple drug candidates tailored for specific types of cancer and chronic inflammatory disorders, underscoring its commitment to addressing unmet medical needs. By concentrating efforts on innovative approaches that modulate immune and inflammatory responses, Rapt Therapeutics plays a significant role in shaping the future of precision medicine in the biopharmaceutical industry. Founded in 2015 and leveraging advanced scientific insights, Rapt Therapeutics represents an important component of the biotech sector's efforts to push boundaries in disease treatment and improve patient outcomes.
Official SEC Documents
Advertisement